Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov:173:105872.
doi: 10.1016/j.phrs.2021.105872. Epub 2021 Sep 4.

Looking deeper into the findings of DARE-19: Failure or an open door to future success?

Theocharis Koufakis  1 , Giuseppe Maltese  2 , Symeon Metallidis  3 , Pantelis Zebekakis  4 , Kalliopi Kotsa  5
Affiliations
Comment

Looking deeper into the findings of DARE-19: Failure or an open door to future success?

Theocharis Koufakis et al. Pharmacol Res. 2021 Nov.
No abstract available

Keywords: COVID-19; Dapagliflozin; SGLT2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Theocharis Koufakis has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly and Novo Nordisk, for advisory boards from Novo Nordisk, and has participated in sponsored studies by Eli-Lilly. Giuseppe Maltese has received honoraria for lectures from AstraZeneca and Novo Nordisk. Kalliopi Kotsa has received honoraria for lectures/advisory boards and research support from Astra Zeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD, and Novo Nordisk. Other authors report no conflict of interest.

Comment on

References

    1. Pirklbauer M. Anti-inflammatory potential of Empagliflozin. Inflammopharmacology. 2021;29(2):573–576. https://dx.doi.org/10.1007%2Fs10787-021-00797-9. - PMC - PubMed
    1. Koufakis T., Pavlidis A.N., Metallidis S., Kotsa K. Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases. Int J. Clin. Pharm. 2021;43(3):764–767. doi: 10.1007/s11096-021-01256-9. - DOI - PMC - PubMed
    1. Koufakis T., Metallidis S., Zebekakis P., Kotsa K. Intestinal SGLT1 as a therapeutic target in COVID-19-related diabetes: a “two-edged sword” hypothesis. Br. J. Clin. Pharm. 2021 doi: 10.1111/bcp.14800. - DOI - PMC - PubMed
    1. Kosiborod M.N., Esterline R., Furtado R.H.M., Oscarsson J., Gasparyan S.B., Koch G.G., Martinez F., Mukhtar O., Verma S., Chopra V., Buenconsejo J., Langkilde A.M., Ambery P., Tang F., Gosch K., Windsor S.L., Akin E.E., Soares R., Moia D., Aboudara M., Hoffmann Filho C.R., Feitosa A., Fonseca A., Garla V., Gordon R.A., Javaheri A., Jaeger C.P., Leaes P.E., Nassif M., Pursley M., Silveira F.S., Barroso W., Lazcano Soto J.R., Nigro Maia L., Berwanger O. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;9(9):586–594. doi: 10.1016/S2213-8587(21)00180-7. - DOI - PMC - PubMed
    1. Bilinski A., Emanuel E.J. COVID-19 and excess all-cause mortality in the US and 18 comparison countries. JAMA. 2020;324(20):2100–2102. doi: 10.1001/jama.2020.20717. - DOI - PMC - PubMed

MeSH terms

Substances